Technology | 2020.09.21
T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy
T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced they have signed an agreement to provide technology transfer and CGMP clinical manufacturing of T-knife’s T1367 T-cell receptor (TCR) program.
(PRWeb September 21, 2020)
Read the full story at https://www.prweb.com/releases/t_knife_and_catalent_sign_technology_transfer_and_manufacturing_agreement_for_autologous_t_cell_receptor_based_cell_therapy/prweb17406593.htm
For more information, please visit
https://www.prweb.com/releases/t_knife_a[...]cell_therapy/prweb17406593.htm
